Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.

Tytuł :
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.
Autorzy :
Ambros IM; Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
Tonini GP; Paediatric Research Institute, Fondazione Città della Speranza, Neuroblastoma Laboratory, Padua, Italy.
Pötschger U; Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
Gross N; Pediatric Oncology Research, Department of Pediatrics, University Hospital, Lausanne, Switzerland.
Mosseri V; Service de Biostatistiques, Institut Curie, Paris, France.
Beiske K; Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Berbegall AP; Department of Pathology, Medical School, University of Valencia-Fundación de Investigación del Hospital Clínico Universitario de Valencia, Valencia, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Bénard J; Département de Biologie et de Pathologie Médicales, Service de Pathologie Moléculaire, Institut Gustave Roussy, Villejuif, France.
Bown N; Northern Genetics Service, Newcastle upon Tyne, United Kingdom.
Caron H; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands.
Combaret V; Centre Léon Bérard, Laboratoire de Recherche Translationnelle, Lyon, France.
Couturier J; Unité de Génétique Somatique et Cytogénétique, Institut Curie, Paris, France.
Defferrari R; Department of Pathology, Istituto G. Gaslini, Genoa, Italy.
Delattre O; INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Paris, France.
Jeison M; Ca-Cytogenetic Laboratory, Pediatric Hematology Oncology Department, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Kogner P; Childhood Cancer Research Unit, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden.
Lunec J; Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Marques B; Centro de Genética Humana, Instituto Nacional de Saude doutor Ricardo Jorge, Lisbon, Portugal.
Martinsson T; Department of Clinical Genetics, Institute of Biomedicine, University of Gothenburg, Sahlgrenska University Hospital, Göteborg, Sweden.
Mazzocco K; Department of Pathology, Istituto G. Gaslini, Genoa, Italy.
Noguera R; Department of Pathology, Medical School, University of Valencia-Fundación de Investigación del Hospital Clínico Universitario de Valencia, Valencia, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Schleiermacher G; INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Paris, France.; Département de Pédiatrie, Institut Curie, Paris, France.
Valent A; Département de Biologie et de Pathologie Médicales, Service de Pathologie Moléculaire, Institut Gustave Roussy, Villejuif, France.
Van Roy N; Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Villamon E; Department of Pathology, Medical School, University of Valencia-Fundación de Investigación del Hospital Clínico Universitario de Valencia, Valencia, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Janousek D; Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
Pribill I; Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
Glogova E; Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
Attiyeh EF; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.
Hogarty MD; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.
Monclair TF; Section for Paediatric Surgery, Division of Surgery, Rikshospitalet University Hospital, Oslo, Norway.
Holmes K; Department of Paediatric Surgery, St George's Hospital, London, UK.
Valteau-Couanet D; Département de Cancérologie de l'Enfant et de l'Adolescent, Gustave Roussy, Villejuif, France.
Castel V; Unidad de Oncologia Pediatrica Hospital Universitario La Fe, Valencia, Spain.
Tweddle DA; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Park JR; Seattle Children's Hospital and University of Washington School of Medicine, Seattle, WA.
Cohn S; Department of Pediatrics, The University of Chicago, Chicago, IL.
Ladenstein R; Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.; Department of Pediatrics, Medical University of Vienna, Vienna, Austria.
Beck-Popovic M; Pediatric Hematology Oncology Unit, University Hospital of Lausanne, Lausanne, Switzerland.
De Bernardi B; Department of Paediatric Haematology and Oncology, Giannina Gaslini Children's Hospital, Genova, Italy.
Michon J; Département de Pédiatrie, Institut Curie, Paris, France.
Pearson ADJ; Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom.
Ambros PF; Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.; Department of Pediatrics, Medical University of Vienna, Vienna, Austria.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Nov 01; Vol. 38 (31), pp. 3685-3697. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology
Original Publication: New York, N.Y. : Grune & Stratton, c1983-
References :
Eur J Cancer. 1995;31A(4):429-34. (PMID: 7576940)
Eur J Cancer. 1995;31A(4):510-5. (PMID: 7576955)
Br J Cancer. 2015 Jan 20;112(2):290-5. (PMID: 25356804)
N Engl J Med. 1996 Jun 6;334(23):1505-11. (PMID: 8618605)
Br J Cancer. 2007 Jul 16;97(2):238-46. (PMID: 17579628)
Cancer Res. 1981 Nov;41(11 Pt 1):4678-86. (PMID: 6171342)
Eur J Cancer. 1997 Oct;33(12):2117-20. (PMID: 9516865)
Clin Cancer Res. 2003 Oct 15;9(13):4835-40. (PMID: 14581355)
Br J Cancer. 2009 May 5;100(9):1471-82. (PMID: 19401703)
Cancer. 1999 Jul 15;86(2):364-72. (PMID: 10421273)
J Clin Oncol. 2000 Jan;18(1):18-26. (PMID: 10623689)
Int J Clin Oncol. 2013 Jun;18(3):389-95. (PMID: 22383024)
J Clin Oncol. 2000 May;18(9):1888-99. (PMID: 10784629)
J Clin Oncol. 1996 Feb;14(2):373-81. (PMID: 8636746)
N Engl J Med. 1999 Jun 24;340(25):1954-61. (PMID: 10379019)
J Clin Oncol. 2012 May 20;30(15):1842-8. (PMID: 22529259)
Int J Cancer. 2012 Oct 1;131(7):1591-600. (PMID: 22234802)
J Clin Oncol. 2009 Jan 10;27(2):298-303. (PMID: 19047290)
Genes Chromosomes Cancer. 2007 Oct;46(10):936-49. (PMID: 17647283)
J Clin Oncol. 2009 Jan 10;27(2):289-97. (PMID: 19047291)
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3368-73. (PMID: 16740759)
Pediatr Blood Cancer. 2015 Sep;62(9):1536-42. (PMID: 25663103)
J Clin Oncol. 2003 Jun 1;21(11):2077-84. (PMID: 12775732)
Br J Cancer. 2012 Oct 9;107(8):1418-22. (PMID: 22976801)
Science. 1984 Jun 8;224(4653):1121-4. (PMID: 6719137)
J Clin Oncol. 2009 Mar 1;27(7):1026-33. (PMID: 19171713)
Br J Cancer. 2008 Oct 7;99(7):1027-33. (PMID: 18766186)
Pediatr Blood Cancer. 2016 Jun;63(6):1019-23. (PMID: 26864375)
J Clin Oncol. 2006 Feb 1;24(4):695-9. (PMID: 16446343)
J Clin Oncol. 2008 Mar 20;26(9):1504-10. (PMID: 18349403)
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12664-9. (PMID: 15314226)
Eur J Cancer. 2009 Nov;45(16):2835-42. (PMID: 19616426)
J Natl Cancer Inst. 1984 Aug;73(2):405-16. (PMID: 6589432)
Int J Cancer. 2016 Jul 1;139(1):153-63. (PMID: 26910568)
N Engl J Med. 1985 Oct 31;313(18):1111-6. (PMID: 4047115)
Med Pediatr Oncol. 2001 Jan;36(1):163-8. (PMID: 11464875)
Cell Tissue Res. 2018 May;372(2):277-286. (PMID: 29305654)
J Clin Oncol. 2005 Nov 20;23(33):8483-9. (PMID: 16293878)
Sci Rep. 2020 Jan 31;10(1):1914. (PMID: 32005943)
J Pediatr Hematol Oncol. 2004 Dec;26(12):791-6. (PMID: 15591897)
J Clin Oncol. 2005 Sep 20;23(27):6459-65. (PMID: 16116153)
Cancer Res. 1993 May 1;53(9):2044-50. (PMID: 8481906)
Br J Cancer. 2011 Dec 6;105(12):1940-8. (PMID: 22146831)
Science. 1993 Jul 16;261(5119):345-8. (PMID: 8332899)
Ann Surg. 2012 Oct;256(4):573-80. (PMID: 22964741)
Lancet Oncol. 2017 Apr;18(4):500-514. (PMID: 28259608)
N Engl J Med. 2005 Nov 24;353(21):2243-53. (PMID: 16306521)
J Clin Oncol. 2019 Jan 10;37(2):115-124. (PMID: 30444686)
Cancer. 1999 Jul 15;86(2):349-63. (PMID: 10421272)
Science. 2018 Dec 7;362(6419):1165-1170. (PMID: 30523111)
Pediatrics. 1959 Jun;23(6):1179-91. (PMID: 13657601)
Int J Cancer. 2001 Mar 1;91(5):680-6. (PMID: 11267980)
J Clin Oncol. 2010 May 10;28(14):2331-8. (PMID: 20351331)
N Engl J Med. 2010 Jun 10;362(23):2202-11. (PMID: 20558371)
Hum Cell. 1998 Sep;11(3):115-24. (PMID: 10086274)
Grant Information :
U10 CA180886 United States CA NCI NIH HHS; U10 CA180899 United States CA NCI NIH HHS
Entry Date(s) :
Date Created: 20200909 Latest Revision: 20201112
Update Code :
20201116
PubMed Central ID :
PMC7605396
DOI :
10.1200/JCO.18.02132
PMID :
32903140
Czasopismo naukowe
Purpose: For localized, resectable neuroblastoma without MYCN amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome.
Patients and Methods: Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group. Genomic data were analyzed using multi- and pangenomic techniques and fluorescence in-situ hybridization in 2 age groups (cutoff age, 18 months) and were quality controlled by the International Society of Pediatric Oncology European Neuroblastoma (SIOPEN) Biology Group.
Results: Patients with stage 1 tumors had an excellent outcome (5-year event-free survival [EFS] ± standard deviation [SD], 95% ± 2%; 5-year overall survival [OS], 99% ± 1%). In contrast, patients with stage 2 tumors had a reduced EFS in both age groups (5-year EFS ± SD, 84% ± 3% in patients < 18 months of age and 75% ± 7% in patients ≥ 18 months of age). However, OS was significantly decreased only in the latter group (5-year OS ± SD in < 18months and ≥ 18months, 96% ± 2% and 81% ± 7%, respectively; P = .001). In < 18months, relapses occurred independent of segmental chromosome aberrations (SCAs); only 1p loss decreased EFS (5-year EFS ± SD in patients 1p loss and no 1p loss, 62% ± 13% and 87% ± 3%, respectively; P = .019) but not OS (5-year OS ± SD, 92% ± 8% and 97% ± 2%, respectively). In patients ≥ 18 months, only SCAs led to relapse and death, with 11q loss as the strongest marker (11q loss and no 11q loss: 5-year EFS ± SD, 48% ± 16% and 85% ± 7%, P = .033; 5-year OS ± SD, 46% ± 22% and 92% ± 6%, P = .038).
Conclusion: Genomic aberrations of resectable non- MYCN- amplified stage 2 neuroblastomas have a distinct age-dependent prognostic impact. Chromosome 1p loss is a risk factor for relapse but not for diminished OS in patients < 18 months, SCAs (especially 11q loss) are risk factors for reduced EFS and OS in those > 18months. In older patients with SCA, a randomized trial of postoperative chemotherapy compared with observation alone may be indicated.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies